The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

Sensitivity and Specificity of the test to diagnose microdeletions (eg. 22q and 5p-) and aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Fetus with confirmed diagnosis of chromosomal abnormality or genetic disorder through karyotype, FISH or positive microarray results after amniocentesis or chorionic villus testing

The biological father of the fetus at least 18 years of age

Able to provide informed consent

Exclusion Criteria:

Women carrying multiples

Pregnancy is a result of IVF with pre-implantation genetic diagnosis

Surrogate/egg or sperm donor used

Previous participation in this study during a previous pregnancy

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01852708